508 related articles for article (PubMed ID: 28520840)
1. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.
Zhao X; Suryawanshi S; Hruska M; Feng Y; Wang X; Shen J; Vezina HE; McHenry MB; Waxman IM; Achanta A; Bello A; Roy A; Agrawal S
Ann Oncol; 2017 Aug; 28(8):2002-2008. PubMed ID: 28520840
[TBL] [Abstract][Full Text] [Related]
2. Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers.
Bei D; Osawa M; Uemura S; Ohno T; Gobburu J; Roy A; Hasegawa M
Cancer Sci; 2020 Feb; 111(2):528-535. PubMed ID: 31773815
[TBL] [Abstract][Full Text] [Related]
3. Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types.
Zhao X; Shen J; Ivaturi V; Gopalakrishnan M; Feng Y; Schmidt BJ; Statkevich P; Goodman V; Gobburu J; Bello A; Roy A; Agrawal S
Ann Oncol; 2020 Feb; 31(2):302-309. PubMed ID: 31959348
[TBL] [Abstract][Full Text] [Related]
4. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
Long GV; Tykodi SS; Schneider JG; Garbe C; Gravis G; Rashford M; Agrawal S; Grigoryeva E; Bello A; Roy A; Rollin L; Zhao X
Ann Oncol; 2018 Nov; 29(11):2208-2213. PubMed ID: 30215677
[TBL] [Abstract][Full Text] [Related]
5. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.
Bi Y; Liu J; Furmanski B; Zhao H; Yu J; Osgood C; Ward A; Keegan P; Booth BP; Rahman A; Wang Y
Ann Oncol; 2019 Apr; 30(4):644-651. PubMed ID: 30715147
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy.
Agrawal S; Feng Y; Roy A; Kollia G; Lestini B
J Immunother Cancer; 2016; 4():72. PubMed ID: 27879974
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
Feng Y; Wang X; Bajaj G; Agrawal S; Bello A; Lestini B; Finckenstein FG; Park JS; Roy A
Clin Cancer Res; 2017 Sep; 23(18):5394-5405. PubMed ID: 28916617
[No Abstract] [Full Text] [Related]
8. Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers.
Osawa M; Hasegawa M; Bello A; Roy A; Hruska MW
Cancer Chemother Pharmacol; 2019 Apr; 83(4):705-715. PubMed ID: 30666395
[TBL] [Abstract][Full Text] [Related]
9. Clinical Benefit-Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors.
Sheng J; Zhang J; Baudelet C; Roy A
J Clin Pharmacol; 2021 Aug; 61(8):1045-1053. PubMed ID: 33501654
[TBL] [Abstract][Full Text] [Related]
10. Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting.
Kato R; Ikarashi D; Matsuura T; Maekawa S; Kato Y; Kanehira M; Takata R; Tokuyama R; Tamai K; Harigai N; Nakazaki Y; Obara W
Transl Oncol; 2020 Jun; 13(6):100771. PubMed ID: 32375081
[TBL] [Abstract][Full Text] [Related]
11. A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors.
Ma Y; Fang W; Zhang Y; Yang Y; Hong S; Zhao Y; Tendolkar A; Chen L; Xu D; Sheng J; Zhao H; Zhang L
Oncologist; 2019 Jul; 24(7):891-e431. PubMed ID: 31048330
[TBL] [Abstract][Full Text] [Related]
12. Flat dose regimen of toripalimab based on model-informed drug development approach.
Li L; Qu J; Song M; Zhao Q; Yang Y; Tan X; Hu Y; Li J; Lin Y; Feng H; Yao S; Keegan P; Chen M
Front Pharmacol; 2022; 13():1069818. PubMed ID: 36712659
[No Abstract] [Full Text] [Related]
13. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non-Small Cell Lung Cancer.
Zhang J; Cai J; Bello A; Roy A; Sheng J
J Clin Pharmacol; 2019 Oct; 59(10):1415-1424. PubMed ID: 31115908
[TBL] [Abstract][Full Text] [Related]
14. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
[TBL] [Abstract][Full Text] [Related]
15. Real-World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma.
Samlowski W; Robert NJ; Chen L; Schenkel B; Davis C; Moshyk A; Kotapati S; Poretta T; Weber JS
Cancer Med; 2023 Feb; 12(3):2378-2388. PubMed ID: 35880244
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
McFarlane JJ; Kochenderfer MD; Olsen MR; Bauer TM; Molina A; Hauke RJ; Reeves JA; Babu S; Van Veldhuizen P; Somer B; Gunuganti V; Schnadig I; George S; Page RD; Arrowsmith E; Jain RK; Zhang J; McHenry MB; Johansen JL; Vogelzang NJ
Clin Genitourin Cancer; 2020 Dec; 18(6):469-476.e4. PubMed ID: 32641261
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma.
Wang X; Feng Y; Bajaj G; Gupta M; Agrawal S; Yang A; Park JS; Lestini B; Roy A
CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):40-48. PubMed ID: 28019090
[TBL] [Abstract][Full Text] [Related]
18. Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma.
Masters JC; Khandelwal A; di Pietro A; Dai H; Brar S
CPT Pharmacometrics Syst Pharmacol; 2022 Apr; 11(4):458-468. PubMed ID: 35166465
[TBL] [Abstract][Full Text] [Related]
19. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of dosing strategy for pembrolizumab for oncology indications.
Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
